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Abstract
Mammalian target of rapamycin (mTOR) is a master regulator of cell growth. Recent reports have defined its important role
in memory cytotoxic T lymphocyte (CTL) differentiation in infections and memory programming. We report that rapamycin
regulated memory CTL programming by IL-12 to a similar level in a wide range of concentrations, and the enhanced
memory CTLs by rapamycin were functional and provided similar protection against Listeria Monocytogenes challenge
compared to the control. In addition, rapamycin-experienced CTLs went through substantially enhanced proliferation after
transfer into recipients. Furthermore, the regulatory function of rapamycin on CD62L expression in memory CTLs was mainly
contributed by the presence of rapamycin in the first 24-hr of stimulation in vitro, whereas the effective window of
rapamycin on the size of memory CTLs was determined between 24 to 72 hrs. In conclusion, rapamycin regulates IL-12-
driven programming of CTLs to a similar level in a wide range of concentrations, and regulates the phenotype and the size
of memory CTLs in different temporal windows.
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Introduction
Induction of functional memory cytotoxic T lymphocytes (CTLs)
is one of the main goals and challenges for vaccination
[1,2,3,4,5,6,7,8,9,10]. The molecular mechanisms for the genera-
tion of memory CTLs are just beginning to be understood. Antigen
and co-stimulation have been shown to induce clonal expansion
[11,12], however, they are not sufficient to drive the differentiation
and development of memory CTLs [5,13,14], in which case a third
signal is needed. Inflammatory cytokines are induced in early
infection [15], and are shown to provide a third signal to CTL fully
activation [5,13]. More importantly, memory CTL response is
abolished in vaccinia virus and Listeria monocytogenes infections when
receptors to both IL-12 and type I IFNs are lacking in CD8 T cells
[16]. Interestingly, when naı ¨ve antigen-specific CD8 T cells were
stimulated for 3 days with antigen, B7 and IL-12 in vitro, these cells
developed into a functional memory population after transfer [16],
indicating that programming of memory CD8 cells may take place
during early activation.
mTOR is a serine/threonine protein kinase, which is highly
conserved in evolution. It is a master regulator of cell growth and
metabolism in response to environment factors, including cellular
energy levels, insulin and other growth factors, amino acids, etc
[17,18,19], which has been extensively investigated as a target in
cancer therapy and transplant tolerance [19,20,21,22]. Recently,
mTOR has been shown to play a critical role in both innate and
adaptive immune responses, notably in the regulation of dendritic
cells, T and B cells [19,23]. As an inhibitor of mTOR signaling,
rapamycin has been commonly used in organ transplantation to
prevent graft rejection, and in cancer therapy [20,24,25]. Surpris-
ingly, administration of rapamycin to mice during LCMV infection
promoted memory CD8 T cells through the inhibition of mTORC1
complex in CD8 T cells [26]. This indicates that memory CTL
formation can be modulated by the regulation of cell metabolisms
[27]. Pearce and colleagues reported that TRAF6 is required for
memory CTL formation by affecting fatty acidoxidation (FAO) [28].
Administration of either antidiabetes drug metformin or rapamycin
replaced this requirement, and restored memory CD8 T cells [28].
mTOR may regulate CD8 T cells by favoring anabolic metabolism
in effectors during antigen and cytokine stimulation. Contraryto that,
memory CD8 T cells can be enhanced by inhibition of mTOR by
rapamycin or AMPK, which switches to catabolic from anabolic
metabolism [27]. However, the way in which metabolic change
regulates memory CTL differentiation remains unknown [27].
Recently, rapamycin was reported to program memory CTLs in
the presence of IL-12 in vitro, by inhibition of CTL effector
function but promoting memory potential, which increased
memory CTL precursors and their survival [29]. However, how
rapamycin regulated memory CTL differentiation, such as its
optimal concentration and temporal requirements, have not been
evaluated. By using the OT1 system, we found that rapamycin
inhibited early activation of CTLs to a similar level in a wide range
of concentrations, which equally enhances the generation of
memory CTLs in the presence of IL-12. Moreover, temporal
requirements are different for rapamycin in regulating the size and
phenotype of memory CTLs.
Materials and Methods
Mice, cell lines, and reagents
OT-I mice (a gift from Dr. Mescher, University of Minnesota)
having a transgenic TCR specific for H-2K
b and OVA257–264 [30]
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(Jackson ImmunoResearch Laboratories, Bar Harbor ME) and
bred to homozygosity. The development of CD8 T cell in all
strains appeared normal with respect to numbers, distribution and
phenotype (data not shown). Mice were maintained under specific
pathogen-free conditions at the University of Maryland, and these
studies have been reviewed and approved by the Institutional
Animal Care and Use Committee. C57BL/6 mice were purchased
from the National Cancer Institute. All directly conjugated
fluorescent antibodies were purchased from BD Biosciences,
eBioscience or Biolegend. Rapamycin was purchased from EMD
(Gibbstown, NJ). The dosage was 75 mg/kg/d [26] for rapamycin
injection through i.p. in recipient B6 mice.
Viruses and bacteria
Recombinant Listeria monocytogenes expressing full-length secreted
ovalbumin (LM-OVA) was used for infection at 5610
5 i.v. for re-
challenge, which was a gift from Dr. Jameson, University of
Minnesota. Spleen cells from memory mice were analyzed by
FACS for the percentage of OT1 cells in live cells, and bulk spleen
cells containing 10
5 memory OT1 cells were transferred into naı ¨ve
B6 mice, which were then challenged by LM-OVA the next day at
5610
5 CFU/mouse i.v. Therefore, the comparison of memory
protection was based on the same amount of memory CTLs
among different groups. The spleen and liver were harvested three
days after LM-OVA challenge, and LM-OVA was cultured using
TSB plates for the comparison of protection as in our previous
report [16].
Naive T cell purification
This was performed in the same way we reported before [16].
Briefly, inguinal, axillary, brachial, cervical, and mesenteric lymph
nodes (LNs) were harvested from WT OT-I mice, pooled, and
disrupted to obtain a single cell suspension. CD8
+CD44
lo cells
were enriched by negative selection using MACS magnetic beads
(Milteny Biotec). In brief, cells were coated with FITC-labeled
antibodies specific for CD4, B220, I-A
b, and CD44. Anti-FITC
magnetic MicroBeads (Miltenyi Biotech) were then added and the
suspension passed through separation columns attached to a
MACS magnet. Cells that did not bind were collected, and were
.95% CD8
+ and ,0.5% CD44
hi. Purified naive OT-I cells were
sorted to reach purity close to 100%.
Real-time RT-PCR
RNA was isolated (Qiagen RNeasy mini kit) and used to
synthesize cDNA (Qiagen QuantiTech Reverse Transcription kit).
Quantitation was performed on a MyiQ
TM Single-Color Real-Time
PCR Detection System (Bio-Rad). Primers used were as follows:
CD62L 59 left primer, 59-gctggagtgacacccttttc-39; CD62L 39 right
primer, 59-gttgggcaagttaaggagca-39; GAPDH 59 left primer, 59-
TGTCTCCTGCGACTTCAACAGC-39; GAPDH 39 right prim-
er, 59-TGTAGGCCATGAGGTCCACCAC-39. Details of the
real-time PCR conditions used are available upon request.
Adoptive transfer and flow cytometric analysis
In vitro activated OT1 cells were adoptively transferred into
normal C57BL/6NCr mice by i.v. (tail vein) injection at 10
6 cells/
mouse. Blood samples were drawn at indicated times, and the
analysis of memory CTLs was based on the spleen and/or blood.
Single cell suspensions were prepared, viable cell counts were
performed (trypan blue) and the percent of OT-I cells in the
sample was determined by flow cytometry. The adoptive transfer
recipients were C57BL/6, and OT-I cells were identified as
CD8
+Thy1.1
+ cells. Background for determining OT-I cell
numbers was determined by identical staining of cells from
normal C57BL/6 mice (no adoptive transfer). Analysis was done
using a FACSCalibur
TM flow cytometer and CELLQuest
TM
software (BD Biosciences) to determine the percent and total OT-I
cells in the samples. Flowjo software (Tree Star Inc.) was used for
analysis of the data.
Intracellular cytokine staining after in vitro re-challenge
Spleen cells from adoptively transferred mice were incubated at
2610
6 cells/ml in RP-10 with 0.2 mM OVA257–264 peptide and
1 ml Brefeldin A (Biolegend) for 3.5 hrs at 37uC. Cells were then
fixed in fixing buffer (Biolegend) for 15 min at 4uC, permeablized
in Saponin-containing Perm/Wash buffer (Biolegend) for another
15 min at 4uC, and then stained with PE-conjugated antibody to
IFNc for 30 min at 4uC. Cells were then washed once with Perm/
Wash buffer, and once with PBS containing 2% FBS.
Intracellular staining for cell signaling molecules
Spleen cells from adoptively transferred mice were washed twice
with cold PBS (4uC), and were then fixed with 2% paraformal-
dehyde for 20 min at 37uC. The cells were chilled on ice for
2 min, and washed twice with cold PBS. Permeablization was
performed using 90% ice-cold methanol (stored at 220u C) on ice
for 30 min. Permeablized cells were washed twice with cold PBS,
and blocked for 10 min with 0.5% BSA-PBS at room temperature.
Staining with primary and secondary antibodies was carried out
for 30 min at 4uC. Cells were washed twice with 0.5% BSA-PBS
after each staining.
In vitro stimulation of naı ¨ve OT-I T cells
Naı ¨ve OT-I.PL T cells were purified as described above and
stimulated for a certain time in vitro in flat-bottom microtiter wells
coated with antigen (DimerX H-2Kb:Ig fusion protein loaded with
OVA257–264 peptide; BD Pharmingen) and recombinant B7-1/Fc
chimeric protein (R&D Systems) as previously described [16].
3610
5 cells in 1.5 ml Allos media were placed in each well and
2.5 U/ml IL-2 added to all wells (24-well plate). Where indicated,
cultures were supplemented with 2 U/ml of murine rIL-12 (R&D
Systems). Rapamycin stock (in DMSO) was diluted with
corresponding culture medium as indicated. For the test of
temporal windows, cells were washed three times after rapamycin
treatment to remove residue rapamycin, which would then be put
into fresh stimulation accordingly. Cells were harvested at the end
of day 3, washed, resuspended at 3.33610
6 cells/ml in DPBS, and
10
6 cells (300 ml) were transferred into C57BL/6 mice by tail vein
injection. Cells that received IL-12 in vitro were termed 3 SI OT-
I, and cells without IL-12 treatment were termed 2 SI OT-I.
Transferred cells were identified by staining with anti-Thy 1.1 and
anti-CD8 mAbs.
Results
Rapamycin delays CTL proliferation during early
activation
mTOR is involved in immune regulation by influencing DC’s
function, especially the production of signal 3, including both IL-
12 and type I IFN [19,23,31]. Consistent with its main function as
a regulator for cell growth and proliferation [18], mTOR is a
mediator in CD4 cell cycle progression driven by integrated signals
from both TCR and CD28 through the PI3K-AKT-mTOR
pathway [19,32]. Recently, inhibition of mTOR by rapamycin in
CD8 T cells was shown to enhance memory T cell differentiation
[26,28]. To investigate the nature of rapamycin regulation on
Rapamycin Regulates Memory CTL Programming
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were labeled with carboxyfluorescein diacetate succinimidyl ester (CFSE),
and stimulated with plate bound antigen and B7 (2-SI/2 signals),
or 2-SI plus IL-12 (3-SI/3 signals). Rapamycin was diluted to span
a wide range, and cell division was examined at day 2 or 3. Cells
did not start to divide until day 2 after stimulation (day 1 data not
shown). In 3-SI stimulation, cells division was delayed by at least
two rounds by rapamycin, and there was not much difference
among concentrations of rapamycin in a range of 12.5 to
1000 ng/ml (Fig. 1A), consistent with previous notion that in the
presence of optimal IL-2, rapamycin can only delay but not
prevent division in CD4 T cells [32,33]. This may reflect the fact
that rapamycin cannot completely inhibit the function of mTOR
[34].
Rapamycin suppressed the cell proliferation of CTLs under 2-SI
stimulation similarly to 3-SI stimulation (Fig.1B), indicating that
rapamycin inhibits CD8 cell cycle progression independently of
third signal cytokine. However, the inhibition of rapamycin on 3-
SI stimulated cells was stronger than on 2-SI, which was indicated
by cell yield after three days of stimulation (Fig. 1C). This may
suggest that rapamycin causes stronger inhibition on the
proliferation of faster dividing cells, as IL-12 enhances CTL
clonal expansion in addition to promote effector functions [11,13].
Rapamycin enhanced the expression of CD62L in 3 signal
stimulations (Fig. 1D), which is consistent with one recent report
[29]. Similar up-regulation of CD62L was observed in 2-SI
stimulation (Fig.1D), and down-regulation of CD62L in both 2-SI
and 3-SI conditions happened only in cells with more than 3
divisions in both cases (Fig.1D). Furthermore, the enhanced
CD62L expression by rapamycin was related to increased CD62L
transcription. The mRNA of CD62L was increased by about 4-
fold when rapamycin was present in 3 signal stimulation for 3 days
(Fig. 1E), indicating that the regulation of CD62L by rapamycin
may be on transcription level.
Rapamycin suppresses effector function of CTLs
IFNc production is a hallmark of type I effector function, which
is not affected by rapamycin treatment for 72 hrs [29]. We found
that rapamycin had inhibitory effects on IFNc production at
48 hrs after 3-SI stimulation in a dose-dependent manner (Fig. 2A),
which was greatly reduced at 12.5 ng/ml, with maximal decrease
at the highest rapamycin concentration (Fig. 2A). This suggests
Figure 1. Rapamycin delays CTL proliferation during early activation. Sorted OT1 cells were labeled with CFSE, then stimulated with 2 SI
(antigen+B7) or 3 SI (2 SI plus IL-12) in the presence of rapamycin at different concentrations. (A–B) Cell proliferation (CFSE dilution) was evaluated at
day 2 and 3. (C) Fold expansion of CTLs 3 days after in vitro stimulation was calculated according to original input. (D) CD62L expression in CFSE
labeled cells at day 3 after stimulation. Numbers beside or above each gate indicates the percentage of gated cells. MFI: Mean Fluorescence Intensity
of the total population. These are representatives of at least three independent experiments with similar results. (E) Transcriptional regulation of
CD62L by rapamycin. OT1 cells were stimulated for 3 days under 3 SI in the presence or absence of rapamycin, and then were harvested for real-time
PCR examination. CD62L and housekeeping gene GAPDH were analyzed in triplicate in real-time RT-PCR assays. Relative mRNA amounts were
normalized with respect to expression levels in Naı ¨ve OT1 control (fold change=1). The results are expressed as mean+SEM of three independent
experiments.
doi:10.1371/journal.pone.0025177.g001
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IFNc. Moreover, although IFNc was greatly inhibited by
rapamycin at 48 hrs (Fig. 2A), there was no difference at 72 hrs
(data not shown), suggesting that mTOR may not be required for
the maintenance of IFNc production. Alternatively, other factor(s)
may compensate this mTOR inhibition.
Granzyme B (GZB) is a molecule directly related to the killing
function of CTLs [13]. Consistent with the recent report by Rao
and colleagues [29], GZB production was suppressed by
rapamycin at 48 hrs (Fig. 2B) and 72 hrs (data not shown). To
confirm that the outcomes were from mTOR function, p70SK6
and 4E-BP1, 2 direct downstream targets of mTOR, were
examined for their expression. Inhibition of mTOR by rapamycin
greatly suppressed the expression of these two molecules at 48 hrs
after stimulation, in a similar pattern by a wide range of
concentrations, supporting that mTOR signal pathway is inhibited
by rapamycin (Fig. 2C and D).
Rapamycin experienced CTLs increase proliferation and
maintain higher CD62L expression during memory
differentiation
The differentiation of memory CTLs takes a long time before
stable memory is established. To track this memory generation
from CTLs regulated by different concentrations of rapamycin, we
examined the kinetics of OT1 cells at different time points after
transfer. In line with a previous report [16], CTLs activated by IL-
12 experienced a significant expansion at day 5 after transfer in
spleen (Fig. 3A), indicating that rapamycin enhanced the
expansion potential of IL-12 conditioned CTLs. This difference
was similarly reflected in blood of recipient mice throughout the
memory differentiation (data not shown). This observation
suggests that the regulatory function of rapamycin on IL-12
conditioned CTLs is likely contributed by an enhanced expansion
potential and subsequent memory differentiation, but we cannot
exclude the possibility of enhancing memory precursors and their
survival [29].
There was a subtle difference (about 20%) in CD62L expression
in spleen cells between rapamycin treated and control 5 days after
transfer (Fig. 3B). This difference maintained throughout the
whole experiment (Fig. 3C). Interestingly, activated OT1 quickly
down-regulated CD62L at day 5 after transfer (Fig. 3B), and then
up-regulated it at day 15, and reached a high level at day 30
(Fig. 3C). This rapamycin-induced CD62L up regulation has been
shown to cause enhanced migration of CTLs to lymphoid tissues
compared to controls [29], consistent with the function of CD62L
as a homing molecule for secondary lymphoid tissues. One of the
major functions of rapamycin is inhibiting cell proliferation, which
was shown in vitro stimulation (Fig. 1). It was possible that
rapamycin-treated CTLs would go through division slower than
no rapamycin control. To address this possibility, CTLs
programmed by IL-12 in the presence or absence of rapamycin
for 3 days were labeled with CFSE, and were then transferred into
recipient B6 mice at 10
6/mouse. At days 1 and 2 after transfer,
OT1 cells in spleen were examined for proliferation. These
stimulated cells started to proliferate 24 hrs after transfer, and
rapamycin-conditioned CTLs were about one round faster than
controls (Fig. 3D), indicating that the difference of memory
generation could be due to difference in the proliferating speed
during memory differentiation. Thus, the enhanced expansion by
rapamycin (Fig. 3A) could be related to increased proliferation
(Fig. 3D) in addition to enhanced survival as suggested by Rao et
al [29].
Rapamycin regulates memory CTL programming in the
presence of IL-12 in a wide range of concentrations
Inhibition of mTOR by rapamycin in the presence of IL-12 has
been shown to enhance memory CTL programming by increasing
the number of precursors and their survival [29]. We sought to
understand how the strength of mTOR inhibition would affect
CTL memory differentiation after programming in vitro. Indeed,
rapamycin significantly enhanced memory programming by IL-12
with no much difference in a wide range of concentrations — 5 to
Figure 2. Rapamycin suppresses effector function of CTLs in wide range of concentration. Sorted OT1 cells were stimulated with
antigen+B7+IL-12 in the presence of rapamycin at different concentrations. Programmed CTLs were harvested at 48 hrs. (A) The expression of IFNc.
(B) The expression of granzyme B (GZB). (C) The expression of P-SK6. (D) The expression of 4E-BP. These are representatives of three independent
experiments with similar results.
doi:10.1371/journal.pone.0025177.g002
Rapamycin Regulates Memory CTL Programming
PLoS ONE | www.plosone.org 4 September 2011 | Volume 6 | Issue 9 | e2517710-fold increase compared to no rapamycin control (Fig. 4A). This
increased memory CTLs could not be contributed only by the
survival of precursors, because the initial transfer number of in
vitro programmed CTLs was only one million, and parking rate
for normal transfer is about 10% [35,36]. Therefore, there is a
significant expansion based on the final memory size (Fig. 4A).
Actually we have shown that CTLs programmed by IL-12 in vitro
undergo vigorous expansion after transfer [16]. Interestingly, the
memory CTLs in all groups demonstrated similar phenotypes in
the expression of CD27, KLRG1 and IFNc (Fig. 4B and C). There
was a consistent marginal up regulation of CD127 (IL-7Ra)i n
rapamycin-induced CTLs, which could be related to improved
survival based on the function of IL-7. Expression of CD62L was
slightly but significantly up regulated by about 20% in rapamycin-
treated memory CTLs at all concentrations (Fig. 4C and D). Equal
numbers of memory CTLs were transferred into recipient naı ¨ve
B6 mice, and the protection of these differentiated memory CTLs
were examined by challenging with LM-OVA. Rapamycin treated
memory CTLs demonstrated equal protection to LM-OVA in
spleen compared to no rapamycin control (Fig. 4E), indicating that
these rapamycin-programmed memory CTLs are equally func-
tional compared to controls. Similar protection was found in liver
(data not shown).
Rapamycin regulates the size of memory CTLs and CD62L
expression in different temporal windows
Rapamycin enhanced IL-12-driven memory programming by 5
to 10-fold (Fig. 4A), but it might not be required to be present for
the whole 3-day culture. We were interested in the effective
temporal window for this regulatory function of rapamycin. Sorted
naı ¨ve OT1 cells were stimulated with antigen, B7 and IL-12 for
three days, in which rapamycin was present for different periods of
time. Activated CTLs were transferred into naı ¨ve B6 mice, and
memory CTLs were analyzed at 30 days after transfer. The
memory size was the same level when rapamycin was present for
the whole 72 or 24–72 hrs. The rest windows, either one day or
two days, all generated significantly lower memory CTLs, at
similar level to no rapamycin control (Fig. 5A) This indicates that
the regulatory effects of rapamycin on memory size is mainly
contributed by its function after 24 hrs.
Figure 3. Rapamycin experienced CTLs have increased proliferation and maintain higher CD62L expression during memory
differentiation. Experimental setting was the same as in Figure 2. Activated CTLs were harvested at day 3 after stimulation in vitro, and were
transferred into naı ¨ve B6 mice at 10
6/mouse. Blood samples were drawn at day 5, 15 and 30 after transfer. (A) Numbers of OT1 cells in spleen 5 days
after transfer. Every group was compared to control group (rapamycin 0). (B) Representative CD62L expression in OT1 cells in blood at day 5 after
transfer. (C) Comparison of CD62L expression in OT1 cells during memory differentiation. ‘‘In vitro’’ represents samples harvested at day 3 after
stimulation in vitro. (D) In a separated experiment, rapamycin+3-SI programmed and control CTLs under 3-SI stimulation were harvested at 72 hrs,
and labeled with CFSE before transferred into B6 mice. CFSE dilution was examined in OT1 cells from spleens at days 1 and 2 after transfer.
Experiments are representatives of at least three independent experiments with similar results (A–C) or one experiment (D). Each value represents the
mean plus the SD of 5 mice per group in C.
doi:10.1371/journal.pone.0025177.g003
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CD62L in a different window. CD62L expression was up
regulated to a similar level when rapamycin was present at the
first or second day in vitro (Fig. 5B and C). In contrast, the
presence of rapamycin at the last 24 hrs seems to have either
minimum or inhibitory effects on CD62L expression, indicating
that effective window differs in the regulation of memory size and
CD62L expression (Fig. 5A–C). Interestingly, memory CTLs
showed similar capacity in IFNc production in all the temporal
windows of rapamycin (Fig. 5D), and expression of CD127 and
KLRG1 was similar in all groups (data not shown). These data
suggest that rapamycin regulates different aspects of memory CTL
programming in different temporal windows.
Injection of rapamycin in recipients can enhance memory
CTL programming by IL-12 after transfer
Although only antigen and B7 are unable to program memory
CTLs [16], it was not known if rapamycin could replace the
function of third signal cytokines, in other words, if rapamycin
could program memory CTLs in the absence of a third signal.
Indeed, CTLs programmed by 2-SI plus rapamycin failed to
form memory CTLs, and had a similar level as 2-SI control
(Fig. 6A), which confirmed that rapamycin cannot replace third
signal to memory CTL programming. This furthers the notion
that inflammatory cytokines are unique in providing a third
signal to full activation of CTL and memory differentiation
[5,37]. However, rapamycin can influence many immune cells
such as DCs [19,23], which may affect memory CTL
differentiation. We sought to find if administration of rapamycin
in vivo could enhance memory CTLs programmed by IL-12 in
vitro. Activated CTLs stimulated by 3-SI were transferred into
recipient mice, and half of them received rapamycin treatment.
Injection of rapamycin caused enhanced memory (Fig. 6B),
suggesting that inhibition of mTOR during memory differenti-
ation can also program memory CTLs. This enhancement was
not as great as in vitro programming (Fig. 4A), which may be due
to the availability of small amount of IL-12 in vivo after transfer.
This low dosage of rapamycin is effective in mTOR regulation,
because it could enhance memory CTLs by 3 to 4-fold in
vaccinia virus infection (unpublished data). In addition, the low
dosage of rapamycin injection caused obvious delay in CTL
proliferation 24 hours after transfer, and the delay was still visible
at day 2, even though no clear individual division was observed
due to the limit of CFSE dilution (Fig. 6C). So, this memory
enhancement was likely related to increased survival by
rapamycin after transfer.
Figure 4. Rapamycin programs memory CTLs in the presence of IL-12 in early activation. Sorted OT1 cells were stimulated with
antigen+B7+IL-12 in the presence of rapamycin at different concentrations. Programmed CTLs were harvested at 72 hrs, and transfer into naı ¨ve B 6
mice at 10
6/mouse through tail injection. (A) Memory OT1 cells in spleen at day 30 after transfer. (B–D) Comparison of molecular expression in
memory CTLs programmed by rapamycin (at 250 ng/ml) with control (no rapamycin). (E) Spleen cells containing 10
5 memory OT1 from (B) were
transferred into naı ¨ve B6 mice, which were challenged the next day with 5610
5 CFU LM-OVA through i.v. Bacterium counts were examined 3 days
after LM-OVA challenge in spleen. Every group was compared to control group (OT1 naı ¨ve–10
5 naive OT1 transfer group). These are representatives
of two independent experiments with similar results. Every group was compared to control group (rapamycin 0) in A and D. Asterisks indicate
statistical significance. *, P,0.05; **, P,0.01; ***, P,0.001. ns: not significant.
doi:10.1371/journal.pone.0025177.g004
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antigen+B7+IL-12 in the presence of rapamycin at 250 ng/ml for different windows. Programmed CTLs were harvested at 72 hrs, and transfer into
naı ¨ve B6 mice at 10
6/mouse. Memory OT1 cells were examined in spleen at day 30 after transfer for analysis of memory size (A), expression of CD62L
(B–C) and production of IFNc (D). Every group was compared to control group (0–72) in A and C.
doi:10.1371/journal.pone.0025177.g005
Figure 6. Injection of rapamycin in recipients can enhance memory CTL programmed by IL-12 after transfer. (A) Sorted OT1 cells were
stimulated with antigen+B7+rapamycin (at different concentration) in the absence of IL-12. Stimulated CTLs were harvested at 72 hrs, and transfer
into naı ¨ve B6 mice at 10
6/mouse. Memory OT1 cells in spleen were examined at day 30 after transfer of CTLs. These are representatives of three
independent experiments with similar results. (B) Sorted OT1 cells were stimulated with antigen+B7+IL-12, and were transferred into recipient B6
mice after 3 days. Half of the recipients received daily injection of rapamycin at 75 ug/kg from 21 to day 10 after transfer [26]. Memory CTLs in spleen
were examined at day 30 after transfer. These are representatives of two independent experiments with similar results. (C) Sorted OT1 cells were
stimulated with antigen+B7+IL-12 for 3 days, and then were labeled with CFSE before being transferred into recipient B6 mice at 10
6/mouse. Half
recipients received daily injection of rapamycin at 75 ug/kg from 21 to day 2 after transfer. CFSE dilution was examined at days 1 and 2 after transfer.
Control: CFSE-labeled naı ¨ve OT1 cells. These are representatives of five animals in each treatment.
doi:10.1371/journal.pone.0025177.g006
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Functional effects of chemicals are normally closely related to
their concentration. As an inhibitor for mTOR, rapamycin is
usually used at around 25 ng/ml for CD8 T cell stimulation
[29,38]. We sought to find if stronger inhibition on mTOR function
could be achieved with increased concentrations of rapamycin.
Surprisingly, no much difference was observed in both in vitro and
in vivo with a 80-fold range of rapamycin from 12.5 to 1000 ng/ml,
suggesting that rapamycin functions at a similar level with this wide
range of concentrations. This is supported by four lines of evidence.
The first evidence is proliferation. All of the doses had similar
inhibition on CTL division (Fig. 1A and B). Second, CD25, GZB
and CD62L were similarly regulated by rapamycin at different
concentrations (Fig. 2B and data not shown). Third, the down-
stream molecules of mTOR pathway, p70SK6 and 4E-BP1 [39],
were suppressed to a similar level. Fourth and foremost, the
rapamycin generated a comparable size of memory CTLs at all
concentrations (Fig. 4A). All of the data point to one single
conclusion that the wide range of rapamycin exerts similar
biological function on CTL activation and programming.
It has been shown that rapamycin cannot completely stop the
progress of cell cycle in CD4 T cells in the presence of optimal IL-
2 [32,33], which may be the same case for CD8 T cells. However,
it is surprising that rapamycin demonstrated almost identical
regulatory functions within a wide range of concentrations on the
expression of many functional molecules, especially memory
programming in this report.
Regulation of rapamycin on memory programming by IL-12
has been suggested to work through inhibition of CTL effector
functions, such as transcriptional factor T-bet, and promoting
eomes expression [29]. In this report, we also found that activation
of IL-12 conditioned CTLs were inhibited by rapamycin,
indicated by reduced production of Granzyme B (Fig. 2B), which
is consistent with a previous report [29]. In addition, there was no
difference in the expression of CD44 and CD127 by rapamycin
treatment (data not shown). IFNc was inhibited at 48 hrs, but not
72 hrs, indicating that mTOR is important for IFNc initial
induction, but not for the later stage, which is in line with a
previous report [29]. The reduced recruitment of STAT4 and
STAT3 by rapamycin [40] may be the mechanism for reduced
IFNc induction at 48 hrs in IL-12 conditioned CTLs (Fig. 2A).
However, we could not rule out the possibility that the reduced
IFNc production may also be contributed by the general inhibition
on protein translation regulated by rapamycin. In addition, during
the continuous presence of rapamycin, IFNc production was back
to normal at 72 hrs (data not shown), suggesting that the
regulation of IFNc induction may use different mechanisms
(factors) at different stages during early activation.
Although memory programming of rapamycin is dependent of
IL-12 (Fig. 6A), the inhibitory function of rapamycin on CTL
proliferation is independent of IL-12. It suppressed proliferation of
2-SI and 3-SI conditioned CTLs at a similar level (Fig. 1A–C).
Clear inhibition of CTL proliferation by rapamycin was observed
at 48 and 72 hrs (Fig. 1A and B), but not 24 hrs (data not shown),
which overlaps with the temporal window (24 to 72 hrs) for the
regulation of rapamycin on memory size (Fig. 5A). This may
suggest that memory regulation by rapamycin is accompanying
CTL dividing. We found that slow dividing CTLs programmed by
IL-12 generated better memory than fast dividing ones after
transferred into recipients (unpublished data). This may be related
to the competition for limited resources for survival and growth, as
fast dividers demand more. So the inhibition of rapamycin on
CTL proliferation could be one of the mechanisms for enhanced
memory programming by IL-12. However, slowing down
proliferation by rapamycin could not generate memory under 2-
SI stimulation (Fig. 6A), supporting the notion that third signal
cytokine is indispensable for memory programming.
Although significantly enhanced memory CTLs were generated
when rapamycin was present for 3 days in IL-12 stimulation, it
might not be required for the whole 3-day incubation. Indeed,
treatment of rapamycin for the last 48 hrs (24 to 72 hrs) induced
comparable memory CTLs to controls (Fig. 5A). The rest of
windows, either 24 or 48 hrs, led to significantly reduced memory
CTLs compared to 3-day rapamycin control (Fig. 5A). Interest-
ingly, Shrikant group found that delayed addition of rapamycin by
12 hrs at the beginning did not affect its regulation on type I effect
function [29], which agrees with the delayed effective window for
rapamycin regulation on memory size (Fig. 5A). However, a
different temporal window is responsible for the regulation of
CD62L expression, the most critical marker for central memory
phenotype [4,14]. CD62L expression was up regulated by the
presence of rapamycin for the first 24 hrs, even though the
number of memory CTLs was low (Fig. 5B and C). This suggests
that short experience of rapamycin may help to generate central
memory CTLs. In contrast, the presence of rapamycin in the last
24 hrs was detrimental for CD62L expression. Therefore,
although the number of memory CTLs programmed by
rapamycin in vitro was similar between 0–72 and 24–72 hrs, the
CD62L expression at the later time was significantly lower,
suggesting that the whole 3 days period may be required for full
differentiation of functional memory CTLs with a central memory
phenotype. Interestingly, the enhanced CD62L expression by
rapamycin seems to be at the transcription level. mRNA of
CD62L was increased by about 4-fold by rapamycin compared to
control (Fig. 1E), consistent with a recent report by Sinclair et al
[39,41]. CD62L transcription is regulated by transcription factor
KLF2, and KLF2 is suppressed by PI3K-mTOR pathway [39,41].
Thus, inhibition of mTOR by rapamycin diminished this
suppression of KLF2, which led to upregulation of CD62L
transcription (Fig. 1E).
In vitro programmed CTLs undergo dramatic proliferation
shortly after transfer, as shown in our previous report [16], and
this proliferation can only happen in IL-12 conditioned CTLs.
Similar results were observed in this report, and rapamycin
treatment dramatically enhanced this proliferation and expansion
(Fig. 3A). Interestingly, the effects of rapamycin on memory CTLs
were more dramatic compared to the effects reported by Rao et al
[29]. We obtained more memory OT1 cells than they did (about 5
fold more), and only one million cells were used for each transfer
whereas 2 millions in their report [29]. It is not clear what caused
this discrepancy, which could be related to differences in
experimental systems. Nevertheless, we observed similar trend
for rapamycin regulation on memory CTL programming by IL-
12, which is related to enhanced expansion potential of CTLs after
transfer. However, we could not exclude the possibility of an
increase in memory CTL precursor and their subsequent survival,
as proposed by Rao and colleagues [29].
Rapamycin cannot replace IL-12 in providing a third signal for
CTL activation — it has to work with a third signal, but not as a
third signal (Fig. 6A). Late supply of rapamycin led to enhanced
memory (Fig. 6B), suggesting that interaction of rapamycin with
small amount of IL-12 or other third signal in vivo could enhance
memory, such as type I IFN. Type I IFN is the major cytokine for
CTL expansion and subsequent memory differentiation in LCMV
infection [42]. Interestingly, administration of rapamycin into
LCMV infected mice results in increased memory CTLs [26]. We
hypothesize that the combination of rapamycin and inflammatory
Rapamycin Regulates Memory CTL Programming
PLoS ONE | www.plosone.org 8 September 2011 | Volume 6 | Issue 9 | e25177cytokine such as IL-12 could serve as adjuvant for vaccination
targeting protective memory CTLs. This adjuvant will be
completely different from traditional adjuvants in that this is
based on interactions between different pathways, rather than
individual pathway initiated by single ligand-receptor recognition.
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